Dexcom posts Q2 earnings beat and lifts 2026 revenue outlook
Dexcom Inc. reported second‑quarter 2026 results with earnings per share of $0.70, surpassing the Wall Street consensus of $0.61. Revenue reached $1.31 billion, topping analysts’ $1.29 billion estimate, and net profit was $249.1 million, or 64 cents per share. The company raised its fiscal‑2026 revenue guidance midpoint to a range of $5.18 billion‑$5.25 billion. Highlights included the unveiling of the next‑generation G8 continuous glucose monitor at its Investor Day, FDA clearance for the Stelo over‑the‑counter CGM for children, and the completion of its acquisition of Nutrisense to add personalized nutrition insights. Dexcom also repurchased roughly $600 million of its own stock during the quarter. The results were driven by a 13.1% year‑over‑year revenue increase, strong international sales growth, and expanding margin outlooks.
Entities: Avidity Partners Management LP · Dexcom Inc. · G8 CGM · G8 continuous glucose monitor · Health Canada · Jake Leach · Mizuho · Nutrisense · Stelo CGM · Stelo over‑the‑counter CGM
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Dexcom adjusted earnings per share were 70¢, 9¢ above Wall Street expectations. (Dexcom Q2 results beat expectations as sales outlook increased)
- [● 2 SOURCES] Dexcom unveiled its next‑generation G8 continuous glucose monitor at Investor Day. (Dexcom Q2 earnings release)
- [● 2 SOURCES] Dexcom reported Q2 profit of $249.1 million, or 64¢ per share. (Dexcom Q2 earnings release)
- [○ 1 SOURCE] Mizuho raised its price target for Dexcom to $95. (Mizuho Raises DexCom (NASDAQ:DXCM) Price Target to $95. 00)
- [● 3 SOURCES] Dexcom Q2 revenue was $1.31 billion. (Dexcom Q2 earnings release)
- [● 2 SOURCES] Dexcom raised its fiscal 2026 revenue guidance midpoint to $5.18‑$5.25 billion. (Dexcom Q2 earnings release)
- [● 3 SOURCES] Dexcom reported EPS of $0.70 for the quarter, beating consensus $0.61. (Dexcom Q2 earnings release)
- [● 2 SOURCES] Dexcom received FDA clearance for its Stelo over‑the‑counter CGM for children. (Dexcom Q2 earnings release)
- [○ 1 SOURCE] Avidity Partners Management LP purchased 90,000 Dexcom shares valued at approximately $5.65 million. (Avidity Partners Management LP bought 90,000 Dexcom shares valued at about $5.652 million)
- [● 2 SOURCES] Dexcom completed its acquisition of Nutrisense. (Dexcom Q2 earnings release)
- [● 2 SOURCES] Dexcom repurchased approximately $600 million of its own stock in Q2. (Dexcom Q2 earnings release)